Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
EUTHROID-1 vs CHOLOXIN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Euthroid-1 is a combination of levothyroxine (T4) and liothyronine (T3), synthetic thyroid hormones that replace endogenous thyroid hormone. T4 is converted to T3 in peripheral tissues, acting on thyroid hormone receptors to regulate gene transcription, metabolism, and growth.
Choloxin (dextrothyroxine sodium) is a synthetic isomer of thyroxine that reduces serum cholesterol levels by increasing hepatic cholesterol catabolism and excretion, likely through enhanced LDL receptor activity and increased conversion of cholesterol to bile acids.
Hypothyroidism, primary, secondary, or tertiary,Thyroid-stimulating hormone suppression in thyroid cancer (off-label)
FDA-approved: Adjunctive therapy in euthyroid patients with primary hypercholesterolemia (elevated LDL) who have not responded to diet and other measures.,Off-label: Treatment of hypothyroidism (though not preferred); investigational use for reducing cardiovascular risk.
One tablet orally once daily, typically in the morning on an empty stomach. Contains 100 mcg levothyroxine and 25 mcg liothyronine.
50-250 mcg/kg orally once daily, adjusted to maintain T4 within normal range.
Terminal elimination half-life: approximately 5-7 days for levothyroxine (T4) and 2-4 days for liothyronine (T3). Clinical context: Steady-state achieved in 6-8 weeks; half-life prolonged in hypothyroidism, shortened in hyperthyroidism.
Terminal elimination half-life is approximately 1-2 hours in euthyroid patients; may be prolonged in hypothyroidism or hepatic impairment.
Levothyroxine is deiodinated to liothyronine in peripheral tissues via iodothyronine deiodinases (DIO1, DIO2). Liothyronine undergoes deiodination and conjugation (glucuronidation, sulfation) in liver.
Primarily hepatic; undergoes deiodination and conjugation to glucuronides and sulfates. Hepatic clearance involves CYP450 enzymes, with a half-life of approximately 12-24 hours.
Renal: ~20-40% as unchanged drug; biliary/fecal: ~40-60% as metabolites and conjugates; total clearance is primarily hepatic.
Primarily renal excretion of conjugated metabolites (70-80% of dose); biliary/fecal excretion accounts for 10-20%; less than 5% excreted unchanged.
>99% bound; T4 bound to thyroxine-binding globulin (TBG: ~70%), transthyretin (10-15%), and albumin (15-20%); T3 binds less avidly to TBG and albumin.
Highly bound (>99%) to thyroxine-binding globulin (TBG), transthyretin, and albumin.
Vd: approximately 0.1-0.2 L/kg for T4; 0.3-0.5 L/kg for T3; reflects distribution primarily into extracellular fluid and limited tissue penetration for T4, wider distribution for T3.
Apparent volume of distribution is 0.10-0.20 L/kg, reflecting extensive tissue binding and distribution.
Oral: 50-80% for T4 (absorption depends on formulation and food); T3 nearly completely absorbed (>90%).
Oral bioavailability is 50-80%, reduced by food, bile acid sequestrants, and certain drugs.
No specific GFR-based dose adjustment required; however, in severe renal failure, monitor thyroid function closely as drug clearance may be altered.
No dose adjustment required for renal impairment as drug is hepatically cleared.
No specific Child-Pugh based dose adjustment; caution in severe hepatic impairment due to altered metabolism of thyroid hormones.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 25-50%. Child-Pugh C: reduce dose by 50-75% and monitor T4 closely.
Weight-based dosing for hypothyroidism: initial 12.5-25 mcg levothyroxine equivalent per day, adjusted based on TSH and free T4 levels. Not recommended for children due to fixed combination ratio.
Neonates: 10-15 mcg/kg/day orally. Infants: 5-10 mcg/kg/day. Children: 2-5 mcg/kg/day. Adjust based on T4 levels.
Start with lower dose (e.g., half tablet) and titrate slowly; monitor for cardiac side effects due to increased sensitivity to thyroid hormones.
Start at 25 mcg/day orally, titrate slowly (every 4-6 weeks) due to increased sensitivity and risk of cardiac adverse effects.
No black box warning.
None specified in FDA labeling.
Cardiovascular toxicity with overdosage; may exacerbate angina, arrhythmias, hypertension. Caution in patients with diabetes mellitus (may increase blood glucose) and adrenal insufficiency. Monitor thyroid function tests and adjust dose.
Cardiac toxicity: Increased risk of arrhythmias, angina, and myocardial infarction, especially in patients with pre-existing cardiovascular disease.,Hyperthyroidism: Can induce thyrotoxicosis if dose is too high or in patients with iodine deficiency.,Drug interactions: Enhances effect of oral anticoagulants (reduce warfarin dose); decreases effect of antidiabetic medications; alters response to digitalis.,Use in pregnancy: Category X – contraindicated due to teratogenic effects.
Untreated adrenal insufficiency, untreated thyrotoxicosis, acute myocardial infarction, hypersensitivity to any component.
Absolute: Euthyroid patients with pre-existing cardiovascular disease (e.g., recent MI, unstable angina, significant arrhythmias).,Absolute: Thyrotoxicosis or iodine deficiency.,Absolute: Pregnancy (Category X).,Relative: Renal or hepatic impairment; concomitant use of anticoagulants (requires close monitoring).
Avoid high-fiber foods, grapefruit juice, and soy products within 4 hours of taking Euthyroid-1 as they may interfere with absorption. Maintain consistent iodine intake; avoid drastic increases in cruciferous vegetables (e.g., broccoli, kale) without medical advice. Calcium-fortified foods and iron-rich foods should be separated by at least 4 hours.
High-fiber foods (e.g., bran, whole grains) may reduce absorption; take levothyroxine separately. Soy-containing products (e.g., tofu, soy milk) and grapefruit juice can alter absorption. Consume these at least 4 hours apart from dosing. Avoid taking with walnuts, cottonseed meal, or concentrated iron-rich foods.
EUTHROID-1 (levothyroxine) is a thyroid hormone replacement. Untreated maternal hypothyroidism is associated with increased risks of miscarriage, fetal neurodevelopmental deficits, preterm delivery, and low birth weight. Levothyroxine itself is not teratogenic; the FDA pregnancy category is A. No increased risk of congenital malformations has been reported with therapeutic doses. In the first trimester, adequate maternal T4 is critical for fetal brain development. In the second and third trimesters, placental transfer of levothyroxine is minimal as fetal thyroid function matures. Untreated hyperthyroidism from over-replacement may increase risk of fetal tachycardia, growth restriction, and preterm birth.
CHOLOXIN (dextrothyroxine) is not recommended during pregnancy. In animal studies, high doses caused fetal resorptions and anomalies. First trimester exposure may increase risk of congenital defects; second and third trimester exposure may impair fetal thyroid function and development. Risk cannot be excluded.
Levothyroxine is excreted into breast milk in low amounts. The milk-to-plasma (M/P) ratio is approximately 0.5. The estimated daily infant dose through breast milk is less than 1% of the maternal dose, which is negligible. No adverse effects in infants have been reported. The American Academy of Pediatrics considers levothyroxine compatible with breastfeeding. Monitoring of infant thyroid function is not routinely required but may be considered if maternal dose is high.
Excretion into human milk is unknown. Due to potential for serious adverse effects in nursing infants, including interference with thyroid function, breastfeeding is contraindicated. M/P ratio not determined.
Pregnancy increases total body water, plasma volume, and renal clearance, and alters thyroid-binding globulin synthesis, leading to increased levothyroxine requirements. Dose adjustments are often needed as early as 4-6 weeks gestation. Typically, the dose is increased by 30-50% from preconception baseline. For patients already on levothyroxine, increase dose by 2 additional tablets per week (e.g., 2 extra doses) or approximately 30% upon confirmation of pregnancy. Monitor TSH every 4-6 weeks and adjust to maintain TSH <2.5 m IU/L in the first trimester and <3.0 m IU/L in later trimesters. After delivery, reduce dose to prepregnancy level and check TSH 6 weeks postpartum.
Pregnancy increases thyroid hormone requirements. Dextrothyroxine is not recommended due to lack of safety data. If used, dose may need increase based on TSH monitoring. Hyperthyroid effects may necessitate dose reduction. Not a standard therapy; levothyroxine is preferred.
Euthyroid-1 contains levothyroxine (T4) and liothyronine (T3) in a fixed 4:1 ratio. Monitor TSH, free T4, and free T3 levels to avoid overtreatment, especially due to T3 component. Use with caution in elderly and patients with cardiovascular disease; start with lower doses. T3 has a shorter half-life (about 1 day) vs T4 (7 days); consider this when interpreting labs. Drug interactions: iron, calcium, antacids, and bile acid sequestrants may reduce absorption; separate by at least 4 hours.
CHOLOXIN (sodium levothyroxine) is a synthetic T4 thyroid hormone. Monitor TSH levels 6-8 weeks after dose changes; target TSH 0.5-2.5 m IU/L for most adults. Administer on empty stomach, 30-60 minutes before breakfast, with water. Avoid concurrent calcium, iron, or antacids within 4 hours. Dose adjustments needed in pregnancy, with T4 dose increase by 30-50% typically. Check for drug interactions with amiodarone, oral contraceptives, and tyrosine kinase inhibitors.
Take exactly as prescribed at the same time each day, usually in the morning on an empty stomach with water.,Do not stop or change dose without consulting your doctor; symptoms may take weeks to improve.,Inform your doctor of all other medications and supplements you take, especially iron, calcium, and antacids.,Report symptoms of hyperthyroidism (rapid heart rate, chest pain, sweating) or hypothyroidism (fatigue, weight gain, cold intolerance).,Store at room temperature away from moisture and heat; keep out of reach of children.
Take levothyroxine on an empty stomach, at least 30-60 minutes before breakfast.,Take with a full glass of water, not with other beverages.,Do not take within 4 hours of calcium or iron supplements, antacids, or sucralfate.,Consistency is key: take the same brand and dose daily; do not switch brands without consulting your provider.,Report symptoms of hyperthyroidism (palpitations, anxiety, weight loss) or hypothyroidism (fatigue, cold intolerance, constipation) promptly.,Do not stop or change dose without talking to your doctor; lab monitoring is required.,If you miss a dose, take it as soon as remembered, but skip if near next dose; do not double.,Inform all healthcare providers you are taking this medication, especially before surgery or starting new meds.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about EUTHROID-1 vs CHOLOXIN, answered by our medical review team.
EUTHROID-1 is a Thyroid Hormone Replacement that works by Euthroid-1 is a combination of levothyroxine (T4) and liothyronine (T3), synthetic thyroid hormones that replace endogenous thyroid hormone. T4 is converted to T3 in peripheral tissues, acting on thyroid hormone receptors to regulate gene transcription, metabolism, and growth.. CHOLOXIN is a Thyroid Hormone Analog that works by Choloxin (dextrothyroxine sodium) is a synthetic isomer of thyroxine that reduces serum cholesterol levels by increasing hepatic cholesterol catabolism and excretion, likely through enhanced LDL receptor activity and increased conversion of cholesterol to bile acids.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between EUTHROID-1 and CHOLOXIN depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of EUTHROID-1 is: One tablet orally once daily, typically in the morning on an empty stomach. Contains 100 mcg levothyroxine and 25 mcg liothyronine.. The standard adult dose of CHOLOXIN is: 50-250 mcg/kg orally once daily, adjusted to maintain T4 within normal range.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between EUTHROID-1 and CHOLOXIN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. EUTHROID-1 is classified as Category C. EUTHROID-1 (levothyroxine) is a thyroid hormone replacement. Untreated maternal hypothyroidism is associated with increased risks of miscarriage, fetal neurodevelopmental deficits,. CHOLOXIN is classified as Category C. CHOLOXIN (dextrothyroxine) is not recommended during pregnancy. In animal studies, high doses caused fetal resorptions and anomalies. First trimester exposure may increase risk of . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.